NCT01239394View on ClinicalTrials.gov

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2015

Conditions
Follicular LymphomaMarginal Zone LymphomaSmall Lymphocytic Lymphoma
Interventions
DRUG

ofatumumab

Weekly infusion for 8 weeks

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01239394 - Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | Biotech Hunter | Biotech Hunter